We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...

Inhibikase Therapeutics announced results from a Phase 2 trial of its Parkinson’s disease drug, risvodetinib, a selective inhibitor of the non-receptor Abelson tyrosine kinases, in a filing to the US ...

The U.S. biotech company Atalanta Therapeutics announced this week that it has raised $97 million in an oversubscribed Series B financing round led by the Swedish investment organization EQT Life ...

The Swiss pharma giant Roche announced yesterday that the first approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD), Elevidys, demonstrated statistically significant ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...